Background-Drug-induced long-QT syndrome (diLQTS) is an adverse drug effect that has an important impact on drug use, development, and regulation. We tested the hypothesis that common variants in key genes controlling cardiac electric properties modify the risk of diLQTS. Methods and Results-In a case-control setting, we included 176 patients of European descent from North America and Europe with diLQTS, defined as documented torsades de pointes during treatment with a QT-prolonging drug. Control samples were obtained from 207 patients of European ancestry who displayed Ͻ50 ms QT lengthening during initiation of therapy with a QT-prolonging drug and 837 control subjects from the population-based KORA study. Subjects were successfully genotyped at 1424 single-nucleotide polymorphisms (SNPs) in 18 candidate genes including 1386 SNPs tagging common haplotype blocks and 38 nonsynonymous ion channel gene SNPs. For validation, we used a set of cases (nϭ57) and population-based control subjects of European descent. The SNP KCNE1 D85N (rs1805128), known to modulate an important potassium current in the heart, predicted diLQTS with an odds ratio of 9.0 (95% confidence interval, 3.5-22.9). The variant allele was present in 8.6% of cases, 2.9% of drug-exposed control subjects, and 1.8% of population control subjects. In the validation cohort, the variant allele was present in 3.5% of cases and in 1.4% of control subjects. Conclusions-This high-density candidate SNP approach identified a key potassium channel susceptibility allele that may be associated with the rare adverse drug reaction torsades de pointes. (Circ Cardiovasc Genet. 2012;5:91-99.)
U nexpected marked prolongation of the QT interval after initiation of drug therapy associated with risk of a morphologically distinct pattern of polymorphic ventricular tachycardia (torsades de pointes) has been recognized since the 1960s. [1] [2] [3] The most common class of drugs causing drug-induced long-QT syndrome (diLQTS) is the membraneactive antiarrhythmic drug category, with an incidence approaching 8% in some reports. [1] [2] [3] However, diLQTS can occur, albeit more rarely, during treatment with various drugs, including many that are not prescribed for cardiovascular indications. 1-3 diLQTS has been a major cause for drug relabeling and withdrawal, creating obstacles for drug development and uncertainties during drug approval and regulatory processes. [1] [2] [3] 
Clinical Perspective on p 99
Clinical studies have identified risk factors for diLQTS such as hypokalemia 4 -6 or female sex, 7 but the phenomenon remains unpredictable in a given individual. Moreover, the congenital long-QT syndromes, usually caused by mutations in ion channel or associated genes, are characterized by the same pattern of torsades de pointes. Because the congenital LQTS may have variable penetrance 8 and some mutation carriers may display normal QT intervals, this finding has lead to the hypothesis that the drug-induced "acquired" LQT syndromes are conditions predisposed by heritable variants in QT-controlling genes. Indeed, screening the common disease genes associated with the congenital syndrome has identified mutations in 5-15% of subjects with diLQTS. 9 -14 One recent study reported congenital LQTS mutations in 8 of 20 (40%) Japanese cases. 15 A second hypothesis is that common genetic variants modulate diLQTS risk, and small studies have identified such variants. 12, 14 In addition, 1 study reported that the extent of QT prolongation among first-degree relatives of subjects with diLQTS was greater than that seen in first-degree relatives of subjects who tolerated QT-prolonging drugs without relevant QT prolongation. 16 In the present study, we tested the second hypothesis, using a large cohort of cases drawn from multiple collaborating sites and interrogating common variants across ion channel and other high-priority candidate genes.
Methods

Subject Sample
The 176 diLQTS patients who constituted the case cohort, defined as documented torsades de pointes during treatment with a drug having known QT-prolonging potential, were from North America or Europe, and all were of self-identified European descent. The diagnosis was ascertained by cardiologists who specialize in clinical electrophysiology at 7 participating centers. The case definition required documented torsades de pointes, associated with any reversible QT prolongation during the drug exposure. Covariates sought included age, sex, self-reported ethnicity, arterial hypertension, history of atrial fibrillation, serum creatinine, and culprit drug, as well as information on serum potassium concentrations (with particular emphasis on hypokalemia) at the time of the index arrhythmia. Written informed consent to participate in the study including the collection and use of DNA samples for genetic analysis was obtained with institutional review board approval at each center.
The drug-exposed control subjects consisted of 207 self-identified European ancestry subjects derived from a clinical study at Vanderbilt University Medical Center, under appropriate institutional re-view board-approved protocols. The study used electronic medical record-based surveillance to identify inpatients in whom QTprolonging antiarrhythmics were being initiated. Patients consenting to participate (91% of those approached) agreed to allow collection of clinical data, including drug-associated QT interval duration changes, as well as DNA samples. For this study, the drug-exposed control cohort was defined by the absence of qualifying arrhythmias, Ͻ50 ms increase in QTc interval using the Bazett formula for heart rate correction, and no QTc interval exceeding 500 ms during drug treatment.
We also used control subjects from the general population. These were recruited from the population-based KORA Study (Cooperative Health Research in the Region of Augsburg), 17 and were all of European descent. In brief, 4856 subjects in 10 subsets of equal size, stratified according to sex and age, underwent a survey in 1994 -1995 (KORA S3) and again in 2004 -2005 (KORA F3). From among the KORA population, we included 837 randomly selected subjects as control subjects, maintaining the original sex distribution. The study was approved by the ethics committee of the Bavarian Medical Association.
Finally, we used cases with diLQTS from the Drug-Induced Arrhythmia Risk Evaluation (DARE) Study, who met the inclusion criteria above, for a validation cohort. 18 These validation cases were compared with healthy population control subjects recruited by DARE from the primary care practices of cases to achieve geographical matches, aiming for a 2:1 to 4:1 ratio of control subjects to cases. Control subjects were excluded if there was any history of ventricular arrhythmia, drug-induced arrhythmia, syncope, or congenital LQTS. All validation control subjects underwent digital 12-lead ECGs and were excluded if there was significant abnormality.
Genotyping
Eighteen candidate genes were studied. These included genes reported to be disease-causing in cardiac arrhythmia syndromes, functionally important subunits of these genes, and genes significantly associated with the QT interval in the general population, based on the results of genome wide association studies (Table 1) . 19, 20 Haplotype tagging SNPs (tagSNPs) were selected to systematically analyze each gene using Tagger, 21 based on HapMap 22 data release No. 20/phase II using the March 2006 NCBI B35 genome assembly and dbSNP build 125 data. The following criteria were applied for tagSNP selection: HapMap CEU population, pairwiseonly tagging with r 2 Ն0.8, and a minor allele frequency (MAF) Ն10%. To account for genetic variation in regions surrounding each gene, we considered upstream and downstream genetic data in the tagging procedure. Included regions were defined by linkage disequilibrium (LD) blocks, as previously reported. 23 We included at least 50 kb of both upstream and downstream information. A total of 1386 SNPs were selected for genotyping using this method. In addition, we included all 38 nonsynonymous SNPs with MAF Ն1%, previously reported in the 18 candidate genes. A summary of all 1424 SNPs chosen for study is presented in Table 1 , and detailed information including a complete SNP list is presented in online-only Data Supplement Table I. Genotyping of all cases, drug-exposed control subjects, and KORA population-based control subjects was performed using a custom Illumina GoldenGate assay (Illumina OPA GS0007558) according to the manufacturer's recommendations, using the Illumina Beadstation 500GX (Illumina Inc, San Diego, CA) in a single laboratory (Genome Analysis Center, Helmholtz Zentrum München, Germany). The Illumina BeadStudio software clustering algorithm was used for initial data analysis. Thereafter, intensity plots of all variants were examined individually, and manual genotype calling was performed if necessary.
Monomorphic SNPs or those with a MAF Ͻ1% and SNPs, as well as samples with call rates Ͻ90%, were excluded from the analysis. A total of 70 SNPs were removed before analysis. Hardy Weinberg equilibrium was calculated for the remaining SNPs, and deviations from Hardy Weinberg equilibrium expectations were noted but not excluded from analyses (online-only Data Supplement Table I ). After filtering, the overall genotyping call rate was 97.1%, and a total of 1354 SNPs had sufficient quality for analysis. Details of SNPs as well as their clustering relative to the 18 selected genes can be found in Table 1 . Clusterplots for SNPs selected for replication are shown in online-only Data Supplement Figure I .
For validation of rs1805128, 57 additional diLQTS cases from the DARE cohort and 211 control subjects were genotyped for KCNE1 D85N (rs1805128), using standard direct Sanger sequencing of the PCR amplicon in both directions. We also used the DARE set to examine whether an initial finding with rs7295250 would replicate. For this experiment, samples were genotyped using the Illumina Infinium Human CVD 50K Bead Array, 24 analyzed with the Illumina platform 500GX (the Biomics Centre, St George's University of London, United Kingdom). Of 138 individuals, 2 had Ͼ10% missing genotypes and were excluded. Another 3 control subjects were excluded, having an overall genotype pattern suggestive of non-European descent despite self-report. Thereafter, 47 cases and 86 control subjects were available with 100% genotyping call rate for rs7295250.
Statistical Analysis
All subjects included in the study were of European descent. We attempted the STRUCTURE 25, 26 and EIGENSTRAT 27 methods to account for population stratification, but no relevant stratification was identified. In particular, the first 5 principal components were nonsignificant.
All tests of association were performed with the use of PLINK. 28 Each SNP was tested for association to diLQTS between cases and control subjects, using logistic regression adjusted for age and sex in 2 different analyses: diLQTS cases versus drug-exposed control subjects, and diLQTS cases versus population control subjects. In addition, we attempted sex-stratified analyses adjusted for age in each analysis group. Bonferroni correction for multiple comparisons would have required an uncorrected probability value of 3ϫ10 Ϫ5 .
Given our sample size and the fact that ours presumably represents already one of the largest collections of diLQTS cases, we applied less stringent criteria for identifying SNPs to be evaluated by replication. We planned to take forward to the DARE follow-up set any SNP with a probability value of Ͻ0.01 for both drug-drugexposed and drug-control population comparisons.
The validation stage associations in the DARE cohort for rs1805128 and rs7295250 were assessed among cases and control subjects only, assuming an additive genetic model adjusted for age and sex.
Results
The clinical characteristics of the cohorts are presented in Table 2 . Among the 176 diLQTS cases, 128 (73%) were female, and the mean age was 63Ϯ17 years. The single most common drug associated with torsades de pointes was sotalol (nϭ52); other common culprit antiarrhythmic drugs included quinidine (nϭ18) and amiodarone (nϭ17). Cumulatively, antiarrhythmics (nϭ107), antipsychotics (nϭ14), and antibiotics (nϭ12) were associated with diLQTS in 133 (76%) of the cases. In 28 cases, combinations of 2 or more culprit drugs were implicated.
Serum potassium was available in 119 cases at the time of the event and was below the laboratory specific reference range in 34 (19.3%) cases. Resting heart rate was different between cases (70.0Ϯ17.4/min), drug-exposed control subjects (80.7Ϯ23.9/min), and population control subjects (69.0Ϯ11.2/min). Atrial fibrillation was more prevalent in the drug-exposed control group (88.9%) compared with the population control group (1.7%) and with the diLQTS cases (53.4%). Quantitatively analyzable 12-lead resting ECG measurements were available in 135 cases, 205 drug-exposed control subjects, and 824 population control subjects. ECG measurements were included before the event or at steadystate postevent and after culprit drug withdrawal. Baseline QT intervals as well as corrected QT intervals using multiple formulas was prolonged at baseline in cases compared with both control groups.
Single SNP tests of association assuming an additive genetic model were performed for 1354 variants across all 18 genes of interest between diLQTS cases and drug-exposed control subjects (Figure, black symbols) . The association results for all SNPs at a significance threshold of PՅ0.01 are shown in Table 3 , and the results for all associations are shown in online-only Data Supplement Table I . All tests of association used a logistic regression model adjusted for age and sex. SNP rs7295250, a variant on chromosome 12 in the genomic region of the L-type calcium channel gene CACNA1C, was associated with the smallest probability value among all tests of association. This variant conferred an odds ratio of 1.88 (95% confidence interval (CI), 1.30 -2.71; Pϭ7.62ϫ10 Ϫ4 ). The strongest effect size within this data set was detected for rs1805128, which is a nonsynonymous coding (missense) SNP in exon 1 of the cardiac ion channel gene KCNE1. This variant leads to an amino acid substitution from aspartic acid to asparagine at position 85 of the translated protein (Asp 85 Asn; D85N). The variant was significantly associated with diLQTS, with an odds ratio of 9.92 (95% CI, 2.36 -41.80; Pϭ1.77ϫ10 Ϫ3 ). The SNP showed a marked difference in allele frequency between diLQTS cases and drug-exposed control subjects: 8.6% versus 2.9%.
In parallel, we performed an analysis comparing diLQTS cases with population control subjects (Figure, gray symbols). Tests of association results with PՅ0.01 are shown in Table 3 , and the complete results are shown in online-only Data Supplement Table I . The most significantly associated variant at this stage was the previously detected rs1805128/ D85N, with an odds ratio of 8.88 (95% CI, 3.26 -24.17; Pϭ1.95ϫ10 Ϫ5 ). The difference in allele frequencies between cases and population-based control subjects was 8.6% versus 1.8%. SNP rs7295250 showed weaker but significant association in the analysis versus population control subjects: odds ratio, 1.56 (95% CI, 1.18 -2.07; Pϭ1.77ϫ10 Ϫ3 ). Other SNPs showed strong associations but were not (or not as significantly) associated in the parallel analysis comparing diLQTS cases and drug-exposed control subjects.
To validate the association between diLQTS and SNPs rs1805128/D85N and rs7295250, we assessed the relationship in the independent DARE sample consisting of 57 diLQTS cases and 211 population-based, matched control subjects. Clinical characteristics of this validation sample are provided in Table 2 . Cases displayed a higher proportion of cardiovascular disease than control subjects, and hypokalemia at the time of the index arrhythmia was identified in 25% of those cases for whom admission potassium levels were available. Amiodarone (51%) and sotalol (26%) were the 2 most common culprit drugs. Six patients (11%) were receiving diuretics, usually in combination with another drug. In 12 patients (21%), more than 1 culprit drug was implicated.
The effect of rs1805128/D85N in the validation analysis showed a trend in the same direction as observed in the discovery analysis (Table 3 ). We identified 1 homozygote and 2 heterozygotes among diLQTS cases and 6 heterozygotes among control subjects. The minor allele frequencies of cases and control subjects in this data set were 3.5% and 1.4%, respectively, which translated into an odds ratio of 1.5 (95% CI, 0.35-6.57; Pϭ0.58).
In an analysis of rs1805128 stratified by sex, we found similar effect estimates and significance levels for both men and women suggesting no major effect modification by sex. In each subgroup, the results were comparable to the main age-and sex-adjusted analysis (data not shown). SNP rs7295250 failed to replicate in the DARE cohort, with a nonsignificant effect estimate in the opposite direction (Table 3 ).
Discussion
In the present study, we tested the hypothesis that common genetic variants modulate the risk for diLQTS. We observed that the KCNE1 variant rs1805128, resulting in D85N, confers substantially increased risk for drug-induced torsades de pointes. The key resources that allowed us to identify this variant as a risk allele were the accumulation of a large set of cases through an international collaboration, large control sets of subjects with drug response phenotypes, and availability of population control subjects.
The D85N variant has been implicated previously as a modulator of QT interval 19, 29, 30 and T-wave morphology. 31 In addition, D85N had been described as a rare variant in a small study of 32 diLQTS cases. 12 One recent study reported that coexpression in heterologous cells of KCNE1 D85N with genes encoding potassium channel pore-forming subunits (KCNQ1 and KCNH2) impaired I Kr and I Ks , 2 key repolarizing potassium currents, and suggested it contributed to the variable penetrance of the congenital LQTS. 32 Life-threatening adverse drug reactions are rare by their nature because high-risk drugs are not generally widely prescribed. Further, many such adverse reactions occur in an unpredictable fashion, and sudden death caused by this mechanism may not be recognized clinically. Thus, the impact of culprit drugs on the balance between risk and benefit of drug therapy in an individual patient has not been predictable a priori. Contemporary genomic approaches to analyze human phenotypes, such as common diseases, rely on discovery and replication cohorts, often accumulating tens of thousands of subjects to validate the predictive power of variants with odds ratios Ͻ2. Accumulating such large numbers of cases is by definition impossible for rare adverse drug effects. 33, 34 Hence, the expectation with the use of either an intensive candidate gene interrogation or even a genome- wide approach is that common contributory variants can be identified only if they confer relatively high odds ratios. Further, demonstration of biological plausibility, as in this study, bolsters an argument that a variant identified in this fashion contributes to the phenotype under study. Other examples of rare adverse drug effects analyzed using genomic approaches include statin-related myopathy 35 and abacavir-related skin reactions. 36 In both cases, individual genetic variants with strong effects on risk and with biological plausibility arguments have been identified. We studied cases of diLQTS caused by a wide range of drugs and drug classes, although the majority was antiarrhythmic-related. Atrial fibrillation was most prevalent in the drug-exposed control group compared with the population control group and with the diLQTS cases. The reason for this distribution pattern was the fact that many diLQTS cases and drug-exposed control subjects received culprit drugs for atrial fibrillation treatment. It is widely accepted that culprit drugs all share a common proximate mechanism, which is inhibition of the rapid component of the cardiac delayed rectifier potassium current, I Kr . [1] [2] [3] This common mechanism justifies the inclusion in this analysis of multiple culprit drugs. High concentrations of offending drugs are also clinical risk factors for diLQTS, although mechanisms producing such elevations are drug-specific. Thus, the analysis we report did not consider variability in drug concentrations. Although the phenotype that we studied required documented torsades de pointes, this arrhythmia has the potential to degenerate to ventricular fibrillation and thus cause sudden cardiac death. Indeed, use of QT-prolonging antipsychotics 37 and of other high potency I Kr blockers 38 has been associated with an increased risk of sudden cardiac death.
Electrophysiological experiments using a range of approaches, from whole hearts 39 -41 to single mammalian cells 42 to computational simulations, 43 support the concept that variability in the extent to which I Kr block prolongs QT interval is determined not only by this specific current but also by multiple other currents whose integrated activity generates normal cardiac repolarization. A framework for analyzing diLQTS susceptibility suggests that multiple mechanisms control normal cardiac repolarization. Thus, loss of a single component in this system is unlikely to cause marked QT derangement; this redundancy has been referred to as "repolarization reserve." 44 As a consequence, individuals with a reduced repolarization reserve, due to common genetic variants or other risk factors such as sex, may display entirely normal QT intervals until drug challenge eliminates the remaining reserve, resulting in marked QT prolongation and torsades de pointes. Recent studies have implicated a second key repolarizing current, I Ks , as a major contributor to repolarization reserve. [41] [42] [43] Our finding that a variant in KCNE1 is a risk factor for diLQTS is entirely consistent with this view and supports the idea of using such a "system" approach 45 to analyze the physiological underpinnings of other rare, previously unpredictable adverse drug effects. Our diLQTS cases presented with significantly prolonged QTc measurements compared with control subjects. We attribute this finding in part to the fact that many ECGs in cases unavoidably were collected when the patients were not entirely off the QT-prolonging drugs. Our findings demonstrate the power both of multi-institutional collaborations to study rare adverse drug effects and of contemporary genomic approaches as a first step to definitive studies to directly test the value of "preprescription genotyping" to optimize drug therapy. Further studies will be required to determine whether preprescription genotyping at this site can reduce the incidence of diLQTS.
Limitations and Conclusions
Restricting our study to participants of European descent does not allow us to make any conclusion with regard to other ethnicities. Although we did not detect relevant population stratification in our cohort, diLQTS cases were of European descent but all population control subjects were Germans only. Current standards in genetic association studies generally require rigorous standards regarding adjustment for multiple comparisons and independent replication. As outlined above, the rarity of our phenotype prevented us from collecting higher numbers of participants to meet this standard. However, the clinical importance of the phenotype justified the acceptance of a trade-off in requirements. In addition, we aimed to minimize false-positive results by using 2 control groups, different in nature, and an independent validation step, which showed consistent but not significant results. As particularly the sample size of the case group was small, we attribute this finding to a limitation of statistical power. In addition to the sample size, also the low frequency of the D85N risk allele is of importance when interpreting the nonsignificant validation. However, the D85N variant is known to modulate potassium current and prolong repolarization. Data attributing risk to this variant in our study and previous work is creating a portfolio of evidence that supports the idea of genotyping subjects at risk before drug exposure. At present, such an option might be still distant but will become more interesting once further supporting replication evidence is available. How much evidence is required to act on a specific variant in this fashion remains controversial and is likely to evolve as genotyping costs and very large databases evolve. 46 We submit that the clarity of our findings would have benefited from additionally adjusted models including ECG measurements such as the QTc interval or other clinical covariates such as potassium levels or concomitant diseases. Because of an excess of missing data in our case samples, we were restricted to a limited adjustment as presented. Future investigations will be required to gain further insight regarding the effect of other factors on the association between D85N and diLQTS. 05 CVD 01). Additional support was provided from Bundesministerium für Bildung und Forschung (BMBF) in the context of the German National Genome Research Network NGFNplus 01GS0838, the LMU Excellence Initiative, and within the Munich Center of Health Sciences (MC Health) as part of LMUinnovativ. The KORA research platform and the MONICA Augsburg studies were initiated and financed by the Helmholtz Zentrum München, German Research Center for Environmental Health, which is funded by the German Federal Ministry of Education and Research and by the State of Bavaria. Additional support for the collection and genotyping of the Miami cohort was provided by the Florida Heart Research Institute. The DARE study was funded by the British Heart Foundation under special project grant SP/02/001. Dr Sinner is supported by the German Heart Foundation.
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